@Toff147 @markeatsmeat 24% of the population has a gene variant SLCO1B1 that allows statins to buildup in the liver, not processing them correctly, causing toxicity. https://t.co/M96TzzWM9s
@VOGT_Guillaume @EVANVAERENBERGH @babgi @Billaut @portablegenomic @bernard_jomard Déjà, voici de manière générale un article scientifique (bien connu, certes) : "Statin-associated muscle symptoms occur in ~10% of patients on statins and constitute the most
RT @PhiLifeSciences: Pharmacogenomics of statins: understanding susceptibility to adverse effects https://t.co/rUHpcXHcEe https://t.co/nFfk…
Pharmacogenomics of statins: understanding susceptibility to adverse effects https://t.co/rUHpcXHcEe https://t.co/nFfk6xlqda
RT @GrupoPKgen_SEFH: Pharmacogenomics of #statins -> #polymorphisms affect statin pharmacokinetics,statin efficacy & end-organ toxicity htt…
RT @Dynamic_DNA_Lab: #Pharmacogenomics of #statins: understanding susceptibility to adverse effects via @DovePress https://t.co/IMr26LGxMt…
RT @GrupoPKgen_SEFH: Pharmacogenomics of #statins -> #polymorphisms affect statin pharmacokinetics,statin efficacy & end-organ toxicity htt…
RT @GrupoPKgen_SEFH: Pharmacogenomics of #statins -> #polymorphisms affect statin pharmacokinetics,statin efficacy & end-organ toxicity htt…
RT @GrupoPKgen_SEFH: Pharmacogenomics of #statins -> #polymorphisms affect statin pharmacokinetics,statin efficacy & end-organ toxicity htt…
#Pharmacogenomics of #statins: understanding susceptibility to adverse effects via @DovePress https://t.co/IMr26LGxMt https://t.co/coTqNfwj7u
RT @GrupoPKgen_SEFH: Pharmacogenomics of #statins -> #polymorphisms affect statin pharmacokinetics,statin efficacy & end-organ toxicity htt…
RT @GrupoPKgen_SEFH: Pharmacogenomics of #statins -> #polymorphisms affect statin pharmacokinetics,statin efficacy & end-organ toxicity htt…
RT @GrupoPKgen_SEFH: Pharmacogenomics of #statins -> #polymorphisms affect statin pharmacokinetics,statin efficacy & end-organ toxicity htt…
Pharmacogenomics of #statins -> #polymorphisms affect statin pharmacokinetics,statin efficacy & end-organ toxicity https://t.co/1U8YxmPyss https://t.co/ivZHqDSUny
#Pharmacogenomics of #statins: understanding susceptibility to adverse effects | PGPM @DovePress https://t.co/3wENToviPs
Pharmacogenomics of statins: understanding susceptibility to adverse effects - Dove Medical Press https://t.co/COWz6binHU
Pharmacogenomics of statins: understanding susceptibility to adverse effects - Dove Medical Press https://t.co/skOvgOuk7Q